Krish Patel

5.1k total citations · 2 hit papers
105 papers, 1.7k citations indexed

About

Krish Patel is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Krish Patel has authored 105 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Genetics, 43 papers in Pathology and Forensic Medicine and 43 papers in Oncology. Recurrent topics in Krish Patel's work include Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (42 papers) and CAR-T cell therapy research (29 papers). Krish Patel is often cited by papers focused on Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (42 papers) and CAR-T cell therapy research (29 papers). Krish Patel collaborates with scholars based in United States, United Kingdom and France. Krish Patel's co-authors include John M. Pagel, David Gius, Phuongmai Nguyen, Kheem S. Bisht, Athanassios Vassilopoulos, Keshav K. Singh, Douglas R. Spitz, Kristi Muldoon‐Jacobs, Nükhet Aykin‐Burns and Seong‐Hoon Park and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Krish Patel

100 papers receiving 1.7k citations

Hit Papers

SIRT3 Is a Mitochondria-Localized Tumor Suppressor Requir... 2010 2026 2015 2020 2010 2025 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. SIRT3 Is a Mitochondria-Localized Tumor Suppressor Required for Maintenance of Mitochondrial Integrity and Metabolism during Stress
    2010 647 citations Krish Patel, Kheem S. Bisht et al. profile →
  2. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
    2025 42 citations Armin Ghobadi, Veronika Bachanová et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Krish Patel United States 20 540 514 427 401 357 105 1.7k
Lin Xia China 28 1.5k 2.7× 615 1.2× 253 0.6× 98 0.2× 137 0.4× 84 2.8k
Simona Ognjanovic United States 17 438 0.8× 458 0.9× 505 1.2× 73 0.2× 213 0.6× 33 1.6k
Noritoshi Kobayashi Japan 28 314 0.6× 972 1.9× 1.0k 2.4× 57 0.1× 166 0.5× 159 2.8k
Chu Matsuda Japan 25 726 1.3× 927 1.8× 144 0.3× 69 0.2× 132 0.4× 167 2.2k
Ying Huang China 25 478 0.9× 1.1k 2.1× 74 0.2× 51 0.1× 537 1.5× 203 2.2k
Jong-Hyeok Kim South Korea 36 568 1.1× 476 0.9× 548 1.3× 54 0.1× 96 0.3× 125 3.5k
Ruey‐Jien Chen Taiwan 19 402 0.7× 176 0.3× 311 0.7× 77 0.2× 58 0.2× 69 1.3k
Xiaokun Ma China 18 355 0.7× 358 0.7× 292 0.7× 61 0.2× 52 0.1× 70 1.1k
Jason Yongsheng Chan Singapore 19 500 0.9× 403 0.8× 131 0.3× 41 0.1× 208 0.6× 107 1.2k
Oscar Alabiso Italy 24 427 0.8× 651 1.3× 280 0.7× 64 0.2× 165 0.5× 60 1.5k

Countries citing papers authored by Krish Patel

Since Specialization
Citations

This map shows the geographic impact of Krish Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krish Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krish Patel more than expected).

Fields of papers citing papers by Krish Patel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krish Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krish Patel. The network helps show where Krish Patel may publish in the future.

Co-authorship network of co-authors of Krish Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Krish Patel. A scholar is included among the top collaborators of Krish Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krish Patel. Krish Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strati, Paolo, Januario E. Castro, Aaron M. Goodman, et al.. (2025). Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. The Lancet Haematology. 12(7). e505–e515. 2 indexed citations
2.
Jain, Nitin, Toby A. Eyre, Katherine B. Winfree, et al.. (2025). Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma. 66(8). 1400–1412. 2 indexed citations
3.
Sharma, Bhavya, et al.. (2025). MM-1180: Persistent Disparities in Multiple Myeloma and Renal Disease Mortality Across US Demographics and Regions (1999–2020): A CDC WONDER Database Analysis. Clinical Lymphoma Myeloma & Leukemia. 25. S971–S972. 1 indexed citations
4.
Wade, Angela, et al.. (2025). Conversational Chatbot with RASA for Educational Facilitation. 267–272.
5.
Phillips, Tycel, Michael Wang, Tadeusz Robak, et al.. (2024). Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial. Haematologica. 110(3). 715–724. 3 indexed citations
6.
7.
Patel, Krish, Swathi Namburi, Tahir Latif, et al.. (2024). Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.. Journal of Clinical Oncology. 42(16_suppl). 7023–7023. 8 indexed citations
8.
Ferrajoli, Alessandra, et al.. (2024). Cumulative review of hypertension in patients with chronic lymphocytic leukemia treated with acalabrutinib. Haematologica. 110(3). 744–748. 2 indexed citations
9.
10.
Wu, James J., et al.. (2024). Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma. Advances in Therapy. 41(8). 3232–3246. 1 indexed citations
11.
12.
Wang, Michael, Nirav N. Shah, Wojciech Jurczak, et al.. (2023). MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment. Clinical Lymphoma Myeloma & Leukemia. 23. S459–S459. 1 indexed citations
13.
14.
Shah, Nirav N., Wojciech Jurczak, Pier Luigi Zinzani, et al.. (2023). Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.. Journal of Clinical Oncology. 41(16_suppl). 7514–7514. 1 indexed citations
15.
Muehlenbein, Catherine E., Catherine C. Coombs, Nirav N. Shah, et al.. (2023). CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 23. S520–S520. 1 indexed citations
16.
Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2021). Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts). Blood. 138(Supplement 1). 2478–2478. 9 indexed citations
17.
Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2021). Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 138(Supplement 1). 2494–2494. 19 indexed citations
18.
Patel, Krish & John M. Pagel. (2021). Current and future treatment strategies in chronic lymphocytic leukemia. Journal of Hematology & Oncology. 14(1). 69–69. 43 indexed citations
19.
20.
Nguyen, Phuongmai, Hengmi Cui, Kheem S. Bisht, et al.. (2008). CTCFL/BORIS Is a Methylation-Independent DNA-Binding Protein That Preferentially Binds to the Paternal H19 Differentially Methylated Region. Cancer Research. 68(14). 5546–5551. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lin Xia Breakdown of academic impact, for papers by Simona Ognjanovic Breakdown of academic impact, for papers by Noritoshi Kobayashi Breakdown of academic impact, for papers by Chu Matsuda Breakdown of academic impact, for papers by Ying Huang Breakdown of academic impact, for papers by Jong-Hyeok Kim Breakdown of academic impact, for papers by Ruey‐Jien Chen Breakdown of academic impact, for papers by Xiaokun Ma Breakdown of academic impact, for papers by Jason Yongsheng Chan Breakdown of academic impact, for papers by Oscar Alabiso
Rankless by CCL
2026